Physician profile
Simran Sehbi
NPI 1215958582
$16,532.93
in general payments reported to CMS, 2019-2025
25 companies · $2,498 in 2025
The $2,498 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $912 · 2021: $1,544 · 2022: $2,912 · 2023: $3,965 · 2024: $4,132 · 2025: $2,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $6.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,588.42 |
| Education | $6.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,790.78 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $2,046.27 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $1,566.36 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,511.98 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,203.71 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $1,143.66 | 2022 | |
| Vanda Pharmaceuticals INC. | $772.17 | 2021-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $761.80 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $714.54 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $646.76 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $571.93 | 2023-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $496.68 | 2024-2025 | Cobenfy |
| Indivior INC. | $284.46 | 2020-2024 | Sublocade |
| Lundbeck LLC | $261.01 | 2020-2025 | Rexulti |
| Tempus Ai, INC | $250.06 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $202.55 | 2021-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $140.71 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $39.28 | 2022-2023 | Belsomra |
| Corium, LLC | $33.31 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $28.62 | 2020 | |
| Braeburn INC. | $24.81 | 2024 | Brixadi |
| Allergan, INC. | $16.08 | 2020 | |
| Shire North American Group INC | $12.86 | 2019 | |
| Bausch Health US, LLC | $12.54 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simran Sehbi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.